ProPublica

Journalism in the Public Interest

Cancel

Johnson & Johnson

Johnson & Johnson, based in New Brunswick, N.J., produces a wide range of consumer products, drugs and medical devices. Two of its divisions, Ortho-McNeil and Ortho-McNeil-Janssen, agreed to pay $81 million in April 2010 to settle civil and criminal charges of illegally promoting the epilepsy drug Topamax. The company has since renamed the divisions. In November 2013, the company also agreed to pay a $2.2 billion fine to resolve criminal and civil allegations relating to the prescription drugs Risperdal, Invega and Natrecor.

Johnson & Johnson is comprised of several subsidiaries that each report information separately. The subsidiaries in Dollars for Docs include Janssen Pharmaceuticals (the largest), Janssen Therapeutics, Janssen Biotech and Janssen Global Services. The units began reporting payments made in 2010 for speaking, consulting, post-marketing safety surveillance, meals and travel.

Each subsidiary reports on a different schedule, but in Dollars for Docs the payments are grouped together as Johnson & Johnson. The subsidiary is listed within each payment page.

Johnson & Johnson's 2013 U.S. sales: $13.9 billion. Source: IMS Health.

See all Johnson & Johnson payments, or visit Johnson & Johnson's transparency page.

Notable drugs

Notable drugs from Janssen Biotech,
a subsidiary of Johnson & Johnson

  • Remicade (plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease/pediatric Crohn's disease, ankylosing spondylitis, ulcerative colitis/pediatric ulcerative colitis)
  • Procrit (anemia, reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery)
  • Stelara (plaque psoriasis)
  • Simponi (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis)
  • Zytiga (prostate cancer)

Notable drugs from Janssen Pharmaceuticals,
a subsidiary of Johnson & Johnson

Notable drugs from Janssen Therapeutics,
a subsidiary of Johnson & Johnson

Payment Reports

2010 Jan. to 2011 Dec., Janssen Global Services

Avg. Quarterly Total
Consulting $140,860 $140,860
$140,860 $140,860

2010 Jan. to Dec. Janssen Biotech

Avg. Quarterly Total
Speaking $725,175 $2,900,700
Consulting $156,047 $624,187
Other $44,204 $176,816
$925,426 $3,701,703

2010 Jan. to Dec. Janssen Pharmaceuticals

Avg. Quarterly Total
Speaking $1,684,425 $6,737,700
Combination $637,544 $2,550,175
Travel $393,540 $1,574,160
Consulting $205,318 $821,272
Meals $66,128 $264,512
Other $2,175 $8,700
$2,989,130 $11,956,519

2010 Jan. to Dec. Janssen Therapeutics

Avg. Quarterly Total
Speaking $500,125 $2,000,500
Consulting $84,125 $336,500
$584,250 $2,337,000

2011 Jan. to Dec. Janssen Biotech

Avg. Quarterly Total
Speaking $1,258,763 $5,035,050
Consulting $323,010 $1,292,039
Other $23,024 $92,097
$1,604,796 $6,419,186

2011 Jan. to Dec. Janssen Pharmaceuticals

Avg. Quarterly Total
Speaking $1,579,769 $6,319,075
Meals $1,101,540 $4,406,159
Consulting $486,550 $1,946,201
Travel $338,025 $1,352,098
Other $3,355 $13,419
$3,509,238 $14,036,952

2011 Jan. to Dec. Janssen Therapeutics

Avg. Quarterly Total
Speaking $682,188 $2,728,750
Consulting $49,038 $196,150
$731,225 $2,924,900

2012 Jan. to Dec. Janssen Global Services

Avg. Quarterly Total
Consulting $21,050 $84,200
$21,050 $84,200

2012 Jan. to Dec. Janssen Therapeutics

Avg. Quarterly Total
Speaking $420,638 $1,682,550
Consulting $24,694 $98,775
$445,331 $1,781,325

2012 Jan. to Dec. Janssen Pharmaceuticals

Avg. Quarterly Total
Speaking $2,826,281 $11,305,125
Meals $1,378,983 $5,515,932
Consulting $479,212 $1,916,850
Travel $430,020 $1,720,081
$5,114,497 $20,457,987

2012 Jan. to Dec. Janssen Biotech

Avg. Quarterly Total
Speaking $873,313 $3,493,250
Consulting $273,325 $1,093,300
$1,146,638 $4,586,550

2013 Jan. to Dec. Janssen Global Services

Avg. Quarterly Total
Consulting $1,500 $6,000
$1,500 $6,000

2013 Jan. to Dec. Janssen Pharmaceuticals

Avg. Quarterly Total
Speaking/Other $3,613,266 $14,453,065
Meals $1,534,401 $6,137,605
Consulting $832,666 $3,330,664
Travel $434,847 $1,739,386
Items, Gifts $189,766 $759,062
$6,604,946 $26,419,783

2013 Jan. to Dec. Janssen Therapeutics

Avg. Quarterly Total
Speaking $126,488 $505,950
Consulting $16,500 $66,000
$142,988 $571,950

2013 Jan. to Dec. Janssen Biotech

Avg. Quarterly Total
Speaking $971,500 $3,886,000
Consulting $304,228 $1,216,912
$1,275,728 $5,102,912

Total Payments by State

State Total
California $11,593,820
New York $10,861,680
Florida $7,942,848
Texas $7,536,817
Pennsylvania $5,391,664
New Jersey $4,275,908
Illinois $3,983,952
North Carolina $3,980,846
Ohio $3,826,226
Michigan $3,291,715
Georgia $3,002,508
Puerto Rico $2,502,189
Tennessee $2,033,759
Massachusetts $2,032,811
Missouri $1,960,722
Maryland $1,910,143
Washington $1,705,368
Connecticut $1,666,604
Indiana $1,665,419
Arizona $1,660,848
Virginia $1,606,745
Alabama $1,602,905
Kentucky $1,338,406
Louisiana $1,285,163
South Carolina $1,246,769
Utah $990,362
Oregon $903,828
Nevada $840,823
Colorado $840,704
Wisconsin $739,649
Oklahoma $723,646
District of Columbia $710,881
Mississippi $640,096
Kansas $534,426
Rhode Island $504,423
Minnesota $439,538
West Virginia $398,499
Arkansas $339,060
Iowa $299,416
New Hampshire $277,380
Nebraska $265,421
Delaware $261,674
New Mexico $210,732
Maine $170,839
Idaho $146,885
Hawaii $142,201
South Dakota $74,020
Vermont $68,509
North Dakota $42,859
Montana $24,069
Wyoming $20,650
Alaska $11,398